MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561887 | Name: PP2 Analog
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PP2 Analog is an analog of PP2 that acts as a protein trafficking modulator.

Chemical Structure

PP2 Analog
PP2 Analog
CAS#309739-67-1

Theoretical Analysis

MedKoo Cat#: 561887

Name: PP2 Analog

CAS#: 309739-67-1

Chemical Formula: C16H17ClN4

Exact Mass: 300.1142

Molecular Weight: 300.79

Elemental Analysis: C, 63.89; H, 5.70; Cl, 11.79; N, 18.63

Price and Availability

Size Price Availability Quantity
200mg USD 1,250.00 2 Weeks
500mg USD 2,650.00 2 Weeks
1g USD 3,650.00 2 Weeks
2g USD 5,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PP2 Analog; PP2-Analog; CHEMBL306012; CHEMBL-306012; CHEMBL 306012;
IUPAC/Chemical Name
7-tert-Butyl-5-(4-chlorophenyl)pyrrolo[2,3-d]pyrimidin-4-amine
InChi Key
CYTZASCNUGMIJP-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H17ClN4/c1-16(2,3)21-8-12(10-4-6-11(17)7-5-10)13-14(18)19-9-20-15(13)21/h4-9H,1-3H3,(H2,18,19,20)
SMILES Code
NC1=C2C(N(C(C)(C)C)C=C2C3=CC=C(Cl)C=C3)=NC=N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
PP2 Analog is an analog of PP2 that acts as a protein trafficking modulator.
In vitro activity:
In this regard, the study’s aims are to explore the mechanism of PP2 on cervical cancer cell growth inhibition by investigating the suppressive divergence among PP1, PP2, and a negative control compound PP3. MTT results showed that three compounds had different inhibitory effects on proliferation of two cervical cancer cells, HeLa and SiHa, and PP2 was most efficient in a time- and dose-dependent manner. Moreover, this study found 10 μM PP2 down-regulated pSrc-Y416 (P < 0.05), pEGFR-Y845 (P < 0.05), and -Y1173 (P < 0.05) expression levels, while 10 μM PP1 down-regulated pSrc-Y416 (P < 0.05) and pEGFR-Y845 (P < 0.05), but not pEGFR-Y1173; 10 μM PP3 down-regulated only pEGFR-Y1173 (P < 0.05). Reference: Mol Cell Biochem. 2011 Feb;348(1-2):11-9. https://pubmed.ncbi.nlm.nih.gov/21052789/
In vivo activity:
PP2-treated rats showed approximately 50% reduction of infarct size on T2-weighted MRI and in TTC staining compared with controls (P < 0.05). Moreover, the neurological score was better in the PP2 group than controls (P < 0.05). PP2 is a potential neuroprotective agent in cerebral ischemia-reperfusion. The interference of PP2 with SFKs and/or other pathways remains to be elucidated. Reference: Acta Neurol Scand. 2004 Sep;110(3):175-9. https://pubmed.ncbi.nlm.nih.gov/15285775/

Preparing Stock Solutions

The following data is based on the product molecular weight 300.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Kong L, Deng Z, Shen H, Zhang Y. Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173. Mol Cell Biochem. 2011 Feb;348(1-2):11-9. doi: 10.1007/s11010-010-0632-1. Epub 2010 Nov 4. PMID: 21052789. 2. Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res. 2002 Jul;8(7):2430-6. PMID: 12114449. 3. Li P, Maitra D, Kuo N, Kwan R, Song Y, Tang W, Chen L, Xie Q, Liu L, Omary MB. PP2 protects from keratin mutation-associated liver injury and filament disruption via SRC kinase inhibition in male but not female mice. Hepatology. 2023 Jan 1;77(1):144-158. doi: 10.1002/hep.32574. Epub 2022 Jun 13. PMID: 35586977. 4. Lennmyr F, Ericsson A, Gerwins P, Akterin S, Ahlström H, Terént A. Src family kinase-inhibitor PP2 reduces focal ischemic brain injury. Acta Neurol Scand. 2004 Sep;110(3):175-9. doi: 10.1111/j.1600-0404.2004.00306.x. PMID: 15285775.
In vitro protocol:
1. Kong L, Deng Z, Shen H, Zhang Y. Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173. Mol Cell Biochem. 2011 Feb;348(1-2):11-9. doi: 10.1007/s11010-010-0632-1. Epub 2010 Nov 4. PMID: 21052789. 2. Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res. 2002 Jul;8(7):2430-6. PMID: 12114449.
In vivo protocol:
1. Li P, Maitra D, Kuo N, Kwan R, Song Y, Tang W, Chen L, Xie Q, Liu L, Omary MB. PP2 protects from keratin mutation-associated liver injury and filament disruption via SRC kinase inhibition in male but not female mice. Hepatology. 2023 Jan 1;77(1):144-158. doi: 10.1002/hep.32574. Epub 2022 Jun 13. PMID: 35586977. 2. Lennmyr F, Ericsson A, Gerwins P, Akterin S, Ahlström H, Terént A. Src family kinase-inhibitor PP2 reduces focal ischemic brain injury. Acta Neurol Scand. 2004 Sep;110(3):175-9. doi: 10.1111/j.1600-0404.2004.00306.x. PMID: 15285775.
Arnold LD, Calderwood DJ, Dixon RW, Johnston DN, Kamens JS, Munschauer R, Rafferty P, Ratnofsky SE. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70. doi: 10.1016/s0960-894x(00)00441-8. PMID: 11012021.